AGRX - Agile Therapeutics' Market Potential And Other News: The Good Bad And Ugly Of Biopharma
Agile Therapeutics Inches Closer to PDUFA for Twirla, Looks Bullish
Agile Therapeutics Inc. (AGRX) is, currently, waiting for the FDA decision for its lead drug candidate Twirla. The PDUFA date for the drug is set for February 16th. Despite several roadblocks faced by the proposed treatment so far, the prognosis is positive for Twirla. Further, the company is looking at a vast and highly lucrative market once the drug is given the nod by the FDA.
The US hormonal contraceptive market was estimated to be worth $7 billion in 2018. The market is